D-galactose induces senescence of glioblastoma cells through YAP-CDK6 pathway
Xingxing Xu,Xiya Shen,Wenjin Feng,Danlu Yang,Lingting Jin,Jiaojiao Wang,Mianxian Wang,Zhang Ting,Feng Xue,Jingjing Zhang,Chaobo Meng,Roumeng Chen,Xinru Zheng,Leilei Du,Lina Xuan,Ying Wang,Tian Xie,Zhihui Huang
DOI: https://doi.org/10.18632/aging.103819
2020-09-29
Abstract:Treatment of glioblastoma using radiotherapy and chemotherapy has various outcomes, key among them being cellular senescence. However, the molecular mechanisms of this process remain unclear. In the present study, we tested the ability of D-galactose (D-gal), a reducing sugar, to induce senescence in glioblastoma cells. Following pretreatment with D-gal, glioblastoma cell lines (C6 and U87MG) showed typical characteristics of senescence. These included the reduced cell proliferation, hypertrophic morphology, increased senescence-associated β-galactosidase activity, downregulation of Lamin B1, and upregulation of several senescence-associated genes such as p16, p53, and NF-κB. Furthermore, our results showed that D-gal was more suitable than etoposide (a DNA-damage drug) in inducing senescence of glioblastoma cells. Mechanistically, D-gal inactivated the YAP-CDK6 signaling pathway, while overexpression of YAP or CDK6 could restore D-gal-induced senescence of C6 cells. Finally, metformin, an anti-aging agent, activated the YAP-CDK6 pathway and suppressed D-gal-induced senescence of C6 cells. Taken together, these findings established a new model for analyzing senescence in glioblastoma cells, which occurred through the YAP-CDK6 pathway. This is expected to provide a basis for development of novel therapies for the treatment of glioblastoma.